Huadong Medicine Co.,Ltd. (000963.SZ) has announced that its subsidiary, Zhejiang Doer Biologics Co., Ltd., recently received a clinical trial approval notice from the National Medical Products Administration for the investigational new drug DR30206 injection. DR30206 is a Class 1 therapeutic biologic product independently developed by Doer Biologics with global intellectual property rights. It is an antibody fusion protein targeting PD-L1, VEGF, and TGF-β. The drug works by blocking the PD-1/PD-L1 signaling pathway to restore the proliferation of exhausted CD8+ T cells, while also binding to free VEGF and TGF-β to reduce tumor angiogenesis and alleviate immune suppression, thereby achieving anti-tumor effects. Results from completed non-clinical studies and ongoing Phase I clinical trials indicate that DR30206 has a clear mechanism of action, demonstrates tumor growth inhibition, and exhibits a favorable safety profile. These findings support further clinical trials of DR30206 in combination with standard chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer. To date, no antibody fusion protein drug simultaneously targeting PD-L1, VEGF, and TGF-β has been approved globally. The approval of this clinical trial in China marks another significant milestone in the development of this novel drug.
Comments